Novo Nordisk A/S Class Action Alert: Robbins LLP Reminds NVO Stockholders of the Pending Lead Plaintiff Deadline
SAN DIEGO, CA / ACCESS Newswire / January 31, 2025 / Robbins LLP reminds stockholders that a class action was filed on behalf of all investors ...
pharmaphorum19h
Novo Nordisk steps up sickle cell push with $1.1bn Forma buy
Novo Nordisk has doubled down on position in the sickle cell disease (SCD) category with a $1.1 billion agreement to acquire Forma Therapeutics, and its therapeutic candidate etavopivat ...
Wall Street Journal19h
Novo Nordisk A/S ADR
$ 84.38-0.07-0.08% ...